


**SUPPLEMENTARY FIGURE 1. Rates of incident laboratory-confirmed COVID-19 cases among immunologic cohorts, by vaccination and previous diagnosis histories — California, May 30–November 20, 2021<sup>\*,†,§</sup>**




\* The SARS-CoV-2 B.1.617.2 (Delta) variant exceeded 50% of sequences in U.S. Department of Health and Human Services Region 9 (containing California) during the week of June 26. <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>

† Estimated hazard rate is laboratory-confirmed COVID-19 cases per 100,000 person-days.

§ <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

**SUPPLEMENTARY FIGURE 2. Rates of incident laboratory-confirmed COVID-19 cases among immunologic cohorts, by vaccination and previous diagnosis histories — New York, May 30–November 20, 2021<sup>\*,†,§</sup>**




\* The SARS-CoV-2 B.1.617.2 (Delta) variant exceeded 50% of sequences in U.S. Department of Health and Human Services Region 2 (containing New York) during the week of July 3, 2021. <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>

† Estimated hazard rate is laboratory-confirmed COVID-19 cases per 100,000 person-days.

§ <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

**SUPPLEMENTARY FIGURE 3. Incident Laboratory-Confirmed COVID-19 Cases among Persons with a Previous COVID-19 Diagnosis, by Time of Previous Diagnosis and Vaccination Status — California and New York, May 30–November 20, 2021**



**SUPPLEMENTARY FIGURE 4. Incident Laboratory-Confirmed COVID-19 among Vaccinated Persons, by Previous Diagnosis and Vaccine Product Received — California and New York, May 30–November 20, 2021**

